Abstract:Background Targeting immune checkpoints for HIV treatment potentially provides a double benefit resulting from the ability to restore viral-specific CD8 + T-cell functions and enhance HIV production from reservoir cells. Despite promising pre-clinical data, PD-1 blockade alone in HIV-1-infected patients with advanced cancer has shown limited benefits in controlling HIV, suggesting the need for additional targets beyond PD-1. CD39 and PD-1 are highly co-expressed on CD8 + T cells in HIV-1 infection. However, the characteristics of CD39 and PD-1 dual-positive CD8 + T-cell subsets in chronic HIV-1 infection remain poorly understood. Methods This study enrolled 72 HIV-1-infected patients, including 40 treatment naïve and 32 ART patients. A total of 11 healthy individuals were included as controls. Different subsets of CD8 + T cells defined by CD39 and/or PD-1 expression were studied by flow cytometry. The relationships between the frequencies of the different subsets and parameters indicating HIV-1 disease progression were analyzed. Functional (i.e., cytokine secretion, viral inhibition) assays were performed to evaluate the impact of the blockade of adenosine and/or PD-1 signaling on CD8 + T cells. Results The proportions of PD-1 + , CD39 + , and PD-1 + CD39 + CD8 + T cells were significantly increased in treatment naïve patients but were partially lowered in patients on antiretroviral therapy. In treatment naïve patients, the proportions of PD-1 + CD39 + CD8 + T cells were negatively correlated with CD4 + T-cell counts and the CD4/CD8 ratio, and were positively correlated with viral load. CD39 + CD8 + T cells expressed high levels of the A2A adenosine receptor and were more sensitive to 2-chloroadenosine-mediated functional inhibition than their CD39 - counterparts. In vitro , a combination of blocking CD39/adenosine and PD-1 signaling showed a synergic effect in restoring CD8 + T-cell function, as evidenced by enhanced abilities to secrete functional cytokines and to kill autologous reservoir cells. Conclusion In patients with chronic HIV-1 infection there are increased frequencies of PD-1 + , CD39 + , and PD-1 + CD39 + CD8 + T cells. In treatment naïve patients, the frequencies of PD-1 + CD39 + CD8 + T cells are negatively correlated with CD4 + T-cell counts and the CD4/CD8 ratio and positively correlated with viral load. Combined blockade of CD39/adenosine and PD-1 signaling in vitro may exert a synergistic effect in restoring CD8 + T-cell function in HIV-1-infected patients.

Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions

Immune checkpoint inhibitors in infectious disease

Interventions during Early Infection: Opening a Window for an HIV Cure?

Immune activation and HIV persistence: implications for curative approaches to HIV infection

Clinical Significance and Management of Low-Level HIV Viremia in the Era of Integrase Strand Transfer Inhibitors

Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells

HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

Research progress on HIV latency-reversing agents and its mechanism

Strategies to limit immune-activation in HIV patients

Understanding and Controlling Chronic Immune Activation in the HIV-Infected Patients Suppressed on Combination Antiretroviral Therapy

HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

Targeting Viral Transcription for HIV Cure Strategies

Persistently Elevated Expression of Systemic, Soluble Co-Inhibitory Immune Checkpoint Molecules in People Living with HIV before and One Year after Antiretroviral Therapy

Reversal of the CD8+ T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways

HIV Pol: does it offer therapeutic targets for HIV?

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection

Selective elimination of host cells harboring replication-competent human immunodeficiency virus reservoirs: a promising therapeutic strategy for HIV cure

Strategies for HIV-1 suppression through key genes and cell therapy